HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: HDAC inhibitors have shown promise in the treatment of various hematological malignancies and solid tumors, such as cutaneous T-cell lymphoma (CTCL) and multiple myeloma, by promoting tumor cell differentiation, inducing cell cycle arrest, and enhancing the immune recognition of cancer cells [162, 163].